ライフサイエンスコーパス: psychiatric disease

1 epilepsy, neurodevelopmental disorders, and psychiatric disease.

2 ping therapeutic interventions to ameliorate psychiatric disease.

3 tecture and altered connectivity profiles in psychiatric disease.

4 ssion, schizophrenia, autism, or other major psychiatric disease.

5 n stratified by previous hospitalization for psychiatric disease.

6 uding noncoding RNAs that may play a role in psychiatric disease.

7 on in HCV-infected patients without previous psychiatric disease.

8 teristic of biological substrates underlying psychiatric disease.

9 es to investigating the neural correlates of psychiatric disease.

10 y reviewed for the subsequent development of psychiatric disease.

11 ic science perspective and in the context of psychiatric disease.

12 ts, which may contribute to neurological and psychiatric disease.

13 reased Arc mRNA), phenotypes associated with psychiatric disease.

14 keptical about the diagnostic value of MR in psychiatric disease.

15 regulation is a hallmark of neurological and psychiatric disease.

16 and the environment relevant to the study of psychiatric disease.

17 otional learning and affective disruption in psychiatric disease.

18 airment, autism, hyperactivity, and possibly psychiatric disease.

19 ereby genetic factors may influence risk for psychiatric disease.

20 ervosa has the highest mortality rate of any psychiatric disease.

21 hypotheses of monoamine signaling underlying psychiatric disease.

22 olipid metabolism in regions associated with psychiatric disease.

23 pathophysiology of pain, ischemic stroke and psychiatric disease.

24 hat could contribute to brain dysfunction in psychiatric disease.

25 ological responses, possibly contributing to psychiatric disease.

26 and to the pathophysiology and treatment of psychiatric disease.

27 utamatergic activity and in neurological and psychiatric disease.

28 f Borna disease virus in human infection and psychiatric disease.

29 ts who had had no history of neurological or psychiatric disease.

30 d in DGS/VCFS, such as learning disorders or psychiatric disease.

31 ed elderly individuals without neurologic or psychiatric disease.

32 e transport have implicated this activity in psychiatric disease.

33 associate with several proteins involved in psychiatric disease.

34 with proteins implicated in contributing to psychiatric disease.

35 ross virtually the full spectrum of parental psychiatric disease.

36 ature of dementia and a prominent feature in psychiatric disease.

37 for working memory impairments in aging and psychiatric disease.

38 ls to study the neural substrates underlying psychiatric disease.

39 our understanding of the pathophysiology of psychiatric disease.

40 ts, which may contribute to neurological and psychiatric disease.

41 he etiology of, or result from, fear-related psychiatric disease.

42 l understanding, diagnosis, and treatment of psychiatric disease.

43 on in four patients with treatment-resistant psychiatric disease.

44 nderstanding of the underlying mechanisms in psychiatric disease.

45 onsumed accidentally or as manifestations of psychiatric disease.

46 ing personalized treatment of neurologic and psychiatric disease.

47 that are dysregulated in stress, reward, and psychiatric disease.

48 ping novel therapeutics for the treatment of psychiatric disease.

49 mplications of insights into the genetics of psychiatric disease.

50 festations of several neurodevelopmental and psychiatric diseases.

51 tterns that are relevant to a broad range of psychiatric diseases.

52 tive diseases, epilepsy or other adult-onset psychiatric diseases.

53 ll as for elucidating the pathophysiology of psychiatric diseases.

54 onsequently, to further our understanding of psychiatric diseases.

55 cortices, in processes that are disrupted in psychiatric diseases.

56 ored for a variety of other neurological and psychiatric diseases.

57 therapy and drug discovery for SCZ and other psychiatric diseases.

58 anders, excluding those diagnosed with these psychiatric diseases.

59 pathophysiology of several neurological and psychiatric diseases.

60 ues for treating aspects of neurological and psychiatric diseases.

61 ling of hippocampal and cortical circuits in psychiatric diseases.

62 eep architecture and memory consolidation in psychiatric diseases.

63 of smooth muscle hyperactivity, and several psychiatric diseases.

64 fying therapeutic avenues for neurologic and psychiatric diseases.

65 onal insights into genes implicated in human psychiatric diseases.

66 rowth, cancer, behavioral abnormalities, and psychiatric diseases.

67 migration defects can cause neurological and psychiatric diseases.

68 els further complicates our understanding of psychiatric diseases.

69 logical disorders, primary brain tumors, and psychiatric diseases.

70 dence of the neurobiologic manifestations of psychiatric diseases.

71 thogenesis of a spectrum of neurological and psychiatric diseases.

72 hich contributes to various neurological and psychiatric diseases.

73 of new models of human neurodegenerative and psychiatric diseases.

74 ated in the pathogenesis of neurological and psychiatric diseases.

75 homeostasis and a variety of neurologic and psychiatric diseases.

76 the pathogenesis of several neurological and psychiatric diseases.

77 en significantly altered in neurological and psychiatric diseases.

78 ns for drug addiction as well as a number of psychiatric diseases.

79 orresponding tissue from individuals without psychiatric diseases.

80 rstanding and treating neurodegenerative and psychiatric diseases.

81 the hyperarousal symptoms of stress-related psychiatric diseases.

82 related to a strong family history of major psychiatric diseases.

83 e treatment of Alzheimer's disease and other psychiatric diseases.

84 diating functions relevant to stress-related psychiatric diseases.

85 re rewarding events are associated with many psychiatric diseases.

86 ences in outcomes relevant to stress-related psychiatric diseases.

87 hlights some insights into its relevance for psychiatric diseases.

88 tified numerous loci that influence risk for psychiatric diseases.

89 tion of glia and neurons in neurological and psychiatric diseases.

90 ding the basic brain processes that underlie psychiatric diseases.

91 ure opportunities in diagnosing and treating psychiatric diseases.

92 View concerns pathogenesis and aetiology of psychiatric diseases.

93 Alcoholism is one of the most prevalent psychiatric diseases.

94 including four candidate causal variants for psychiatric diseases.

95 D and may also be recruited for fear-related psychiatric diseases.

96 th a broad spectrum of neurodegenerative and psychiatric diseases.

97 stage for the development of stress-induced psychiatric diseases.

98 ht play a role in the development of several psychiatric diseases.

99 ave received attention as risk modulators in psychiatric diseases.

100 xiety disorders represent the most common of psychiatric diseases (28% lifetime prevalence) and contr

101 s and their pathology due to neurological or psychiatric diseases across species.SIGNIFICANCE STATEME

102 3B p.Y129S (c.386A>C, rs11767445), linked to psychiatric disease, also forms A3B2 receptors on the pl

103 ies linking ankyrin-G genetic variation with psychiatric disease and abnormal neurodevelopment.

104 gnitive/emotional roles of the cerebellum in psychiatric disease and drug abuse.

105 ter understand the biological basis for this psychiatric disease and its cognitive manifestations usi

106 Associations between parental psychiatric disease and offspring violent offending were

107 cover neuronal phenotypes from patients with psychiatric disease and prospects for the use of this pl

108 DISC1 influences susceptibility to psychiatric disease and related phenotypes.

109 ations between the full spectrum of parental psychiatric disease and risks of attempted suicide and v

110 on as a promising intermediate phenotype for psychiatric disease and suggest a pathophysiologic mecha

111 healthy subjects: one playing patients with psychiatric disease and the other playing healthy contro

112 nships between the full spectrum of parental psychiatric disease and these 2 related outcomes are unc

113 ept can refine current inheritance models of psychiatric diseases and facilitate the development of b

114 potential in furthering our understanding of psychiatric diseases and in developing new therapies.

115 ,526 could affirm the role of CRF in certain psychiatric diseases and may be of significant value in

116 hPSD mutations cause 133 neurological and psychiatric diseases and were enriched in cognitive, aff

117 e for modeling and treating neurological and psychiatric diseases and will highlight areas of caution

118 iation between dopamine and neurological and psychiatric diseases and with substance abuse make it an

119 mechanisms of brain networks with respect to psychiatric diseases and--as a novelty--extrapolates to

120 Patients with psychiatric diseases and/or substance abuse have an incr

121 percent after a spouse's hospitalization for psychiatric disease, and 5.0 percent after a spouse's ho

122 percent after a spouse's hospitalization for psychiatric disease, and 8.6 percent after a spouse's ho

123 lationships between experience, physical and psychiatric disease, and aging.

124 er disease, Parkinson disease, brain tumors, psychiatric disease, and numerous degenerative neurologi

125 This communication is impaired in psychiatric disease, and ongoing studies have proposed t

126 ie many of the molecular changes observed in psychiatric disease, and that therapeutic regulation of

127 Their involvement in major neurological and psychiatric diseases, and importance as therapeutic targ

128 diseases, hypertension, autoimmune diseases, psychiatric diseases, and some infectious diseases), are

129 isease, diabetes, asthma, cardiovascular and psychiatric disease; and quantitative traits like blood

130 SC1 dysfunction might increase propensity to psychiatric disease are not completely understood; howev

131 Several known genetic risk factors for psychiatric disease are related to the regulation of act

132 Many neurological and psychiatric diseases are associated with clinically dete

133 This suggests that neurologic and psychiatric diseases are characterized by altered intera

134 interactions between metabolic disorders and psychiatric diseases are discussed.

135 Effective drug treatments for many psychiatric diseases are lacking, and the emerging tools

136 DBS to rodent models.SIGNIFICANCE STATEMENT Psychiatric diseases are linked to abnormalities in spec

137 Psychiatric diseases are multifaceted disorders with com

138 ies have also shown that common physical and psychiatric diseases are partly heritable [6].

139 ex, polygenic disorders responsible for such psychiatric diseases as schizophrenia, manic depressive

140 early differentiation of bvFTD from primary psychiatric disease, as bvFTD therapies will likely be m

141 erapeutic potential for the vast spectrum of psychiatric diseases associated with an imbalance betwee

142 targets for the treatment of stress-related psychiatric diseases associated with cognitive dysfuncti

143 um has long been used as a treatment for the psychiatric disease bipolar disorder.

144 tion as causes not only of neurological (and psychiatric) diseases but also of age-related neurodegen

145 ecific to SLE and tend to be associated with psychiatric disease, but not exclusively so.

146 ground in how we untangle the complexity of psychiatric diseases; by making thalamic circuits access

147 isrupt adolescent sleep patterns, exacerbate psychiatric disease, cause physiologic dependence, and i

148 ividuals without evidence of neurological or psychiatric diseases (chi(2) = 19.25, P < 0.001).

149 merging inconsistency between behavior-based psychiatric disease classification system and the underl

150 many to speculate that concurrent delirium, psychiatric disease, dementia, or a second lesion is req

151 ations and family history of broadly defined psychiatric disease (depressive disorders, bipolar disor

152 Here we review recent advances in modeling psychiatric disease, discuss the utility and limitations

153 of this tripartite network are disrupted in psychiatric diseases, divorcing areas that integrate emo

154 patients with substance use disorders and/or psychiatric diseases do not differ regarding sustained v

155 ponses are linked to a number of somatic and psychiatric diseases, emphasizing the importance of prec

156 's disease, autism and related disorders and psychiatric disease, epilepsy, migraine and trauma.

157 observed in patients and in animal models of psychiatric disease, evidence for abnormalities in funct

158 Knowledge of psychiatric disease genetics has advanced rapidly during

159 Genetic variants that underlie psychiatric disease have proven particularly difficult t

160 percent confidence interval, 1.11 to 1.18), psychiatric disease (hazard ratio, 1.19; 95 percent conf

161 Physical triggers, acute neurologic or psychiatric diseases, high troponin levels, and a low ej

162 retrieval, and the pathophysiology of major psychiatric diseases; however, no such direct projection

163 is involved in a variety of neurological and psychiatric diseases; however, the mechanistic link betw

164 of the pathways leading to PGE2 synthesis in psychiatric disease, immunohistochemistry and immunoblot

165 us, Tbx1 and Gnb1l are strong candidates for psychiatric disease in 22q11DS patients and candidate su

166 anges in a current thought to be relevant to psychiatric disease in a partial model of schizophrenia.

167 Atopic dermatitis (AD) has been linked with psychiatric disease in adults.

168 ted factors associated with neurological and psychiatric disease in general.

169 ACNA1C has consistently been associated with psychiatric disease in genome-wide association studies.

170 placenta and not the fetus to reduce risk of psychiatric disease in later life.

171 Our data suggest both a possible role of psychiatric disease in predisposing patients to critical

172 ients and candidate susceptibility genes for psychiatric disease in the wider population.

173 and development of several neurological and psychiatric diseases in humans.

174 e strains and have implications for modeling psychiatric diseases in mice.

175 ural and behavioral deficits associated with psychiatric diseases in the adult.

176 The biggest challenge for modeling psychiatric diseases in vitro is finding and establishin

177 ram (EEG) is associated with common, complex psychiatric diseases including alcoholism, schizophrenia

178 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syn

179 are commonly used drugs for the treatment of psychiatric diseases including major depressive disorder

180 Finally, various neurologic and psychiatric diseases including mild traumatic brain inju

181 a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression.

182 and experience (anhedonia) can contribute to psychiatric diseases, including depression and schizophr

183 isorder is related to the pathophysiology of psychiatric diseases, including major depression, substa

184 In addition, the use of DBS in a number of psychiatric diseases, including obsessive-compulsive dis

185 Studies have shown that a history of psychiatric disease increases the risk of suicide in a p

186 therapeutics indicated for the treatment of psychiatric disease (IRR = 3.78; 95% CI, 1.77-8.06; P <

187 Maternal psychiatric disease is associated with adverse pregnancy

188 A likely role for Tbx1 haploinsufficiency in psychiatric disease is further suggested by the identifi

189 rs contribute to the alterations observed in psychiatric diseases is unknown.

190 which is often disturbed in neurological and psychiatric diseases like depression, schizophrenia and

191 novo mutations of NMDAR subunits and severe psychiatric diseases, little is known about their pathog

192 of the stop codon, which was associated with psychiatric diseases marked by impulsivity in both popul

193 europsychological deficits in the context of psychiatric disease may be associated with suicide risk.

194 pe to include behavioral correlates of human psychiatric diseases, much of this consistency ends.

195 mood disorders (n = 6) with subjects without psychiatric disease (n = 8).

196 ariants that contribute to the expression of psychiatric disease, no consistent associations have bee

197 he presence of one or more genes involved in psychiatric diseases on the q arm of chromosome 12 and p

198 The subjects had no history of psychiatric disease or abnormal collecting behaviour pri

199 n young patients present with liver disease, psychiatric disease, or a movement-disorder type of neur

200 positively associated with family history of psychiatric disease (P = 0.003).

201 Circuit dysfunction models of psychiatric disease posit that pathological behavior res

202 Interestingly, PDE11A KO mice show subtle psychiatric-disease-related deficits, including hyperact

203 is one reason that the causative factors of psychiatric diseases remain obscure.

204 tality when accounting for previous maternal psychiatric disease remains unknown.

205 effort for many years, the etiology of major psychiatric diseases remains unknown.

206 portunities for developing animal models for psychiatric disease research with the goal of attaining

207 Using an animal model of a psychiatric disease risk factor, prenatal maternal immun

208 A sequences have a well-demonstrated role in psychiatric disease risk, for even the most heritable me

209 subjects showing no signs of a neurologic or psychiatric disease served as controls.

210 m and common features shared by FTD and some psychiatric diseases, starting from Pick's clinical desc

211 tion represent a core symptom of a number of psychiatric disease states, including autism, schizophre

212 e HPA abnormalities underlying metabolic and psychiatric disease states.

213 ations of emotional processing underlie many psychiatric disease states.

214 Many psychiatric diseases stem from a multifactorial origin,

215 e lack of quantitative objective measures of psychiatric diseases such as anxiety and depression is o

216 Severe behavioural deficits in psychiatric diseases such as autism and schizophrenia ha

217 types 5 and 7, and may also be implicated in psychiatric diseases such as bipolar affected disorder a

218 sion mutations may have an etiologic role in psychiatric diseases such as bipolar disorder, schizophr

219 r 1 (CRFR1) is a target for the treatment of psychiatric diseases such as depression, schizophrenia,

220 derstanding the neural basis of a variety of psychiatric diseases, such as addiction or anxiety disor

221 a specific cognitive deficit seen in several psychiatric diseases, such as addiction, attention-defic

222 ficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and sc

223 ess has a crucial role in the development of psychiatric diseases, such as anxiety and depression.

224 Ns has been associated with neurological and psychiatric diseases, such as epilepsy, schizophrenia, a

225 y impair cognition and increase the risk for psychiatric diseases, such as schizophrenia.

226 ain, increases in food intake and hunger, or psychiatric disease, suggesting that AAPs exert direct e

227 oresight, is an important feature of several psychiatric diseases, suicidality and violent behaviour.

228 standing circuit-level substrates underlying psychiatric disease symptoms.

229 Schizophrenia is a devastating psychiatric disease that affects 0.5-1% of the world's a

230 Schizophrenia is a severely debilitating psychiatric disease that is hypothesized to have its roo

231 gy and treatment of diverse neurological and psychiatric diseases that are characterized by altered o

232 a platform for therapeutic investigation in psychiatric diseases that involve impairments in PFC-dep

233 s has been implicated in diverse medical and psychiatric diseases, these sex differences in CRF1 sign

234 al neurogenesis and contribute to aspects of psychiatric disease through abnormal production of D-ser

235 s and therapies of multiple neurological and psychiatric diseases through translational research.

236 erapy increasingly used for neurological and psychiatric disease, traditionally is divided into invas

237 in women with a previous hospitalization for psychiatric disease was 0.92 (95% CI, 0.66-1.28; P = .62

238 anking CNV from the family-based analysis in psychiatric disease was obtained through analysis of 408

239 abolic effects independent of weight gain or psychiatric disease, we administered olanzapine, aripipr

240 To advance our understanding of psychiatric disease, we advocate a more systematic appro

241 ottish family that was associated with major psychiatric disease, we are starting to obtain credible

242 evelopment may contribute to the etiology of psychiatric disease, we investigated the function of a h

243 plied to alcohol use disorder (AUD) or other psychiatric diseases, where there is a critical need for

244 izophrenia is an etiologically heterogeneous psychiatric disease, which exists in familial and nonfam

245 Additionally, most genetic determinants of psychiatric disease will probably be of modest effect an

246 most promising advances in neurological and psychiatric diseases will require advances in neuroscien

247 Major depression disorder is a common psychiatric disease with a major economic impact on soci

248 Schizophrenia is a debilitating psychiatric disease with a strong genetic contribution,

249 der (BP) are common, disabling and heritable psychiatric diseases with a complex overlapping polygeni

250 mediate threat and represent the most common psychiatric diseases, with an estimated 28% lifetime pre

251 is a major risk factor for the incidence of psychiatric diseases, yet acute stress episodes may have